The global Cluster Headache Market is estimated to be valued at US$ 402.12 Mn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Cluster headache is a painful headache condition characterized by severe or very severe pain on one side of the head. It usually affects one side of the face or head, behind and around the eye. The headaches typically strike quickly and last between 15 minutes and 3 hours. Factors such as unhealthy lifestyle habits like tobacco, alcohol consumption and exposure to allergens are major causes of cluster headaches. Treatment options include oxygen therapy, nerve blocks and medications. Preventive and acute medication is widely given for cluster headache management.
Market key trends:
One of the major trend gaining traction in the cluster headache market is increasing use of preventive treatment. Preventive treatment aims to reduce the frequency and severity of cluster headaches. Medications such as verapamil, lithium carbonate, and methysergide are commonly used as preventive treatment for cluster headaches. According to a research article published in Neurology in 2019, 70% of cluster headache patients required preventive treatment among which non-invasive vagus nerve stimulation (nVNS) was found to be effective in reducing attack frequency and severity. Growing awareness about benefits of preventive treatment is contributing to the market growth.
Threat of new entrants: The cluster headache market has high product differentiation and well established patents. This reduces the threat of new entrants.
Bargaining power of buyers: Buyers have moderate bargaining power given the availability of therapies from multiple pharmaceutical companies. However, the severity of cluster headaches means patients have inelastic demand.
Bargaining power of suppliers: Pharmaceutical companies have significant bargaining power as suppliers due to intellectual property protections and differentiation in formulations.
Threat of new substitutes: There are limited new substitutes for cluster headache treatment. Innovation in gene therapy and neurostimulation may provide new options but currently there are no close substitutes.
Competitive rivalry: The market is dominated by large pharmaceutical companies. Competition is high based on marketing of new formulations and delivery mechanisms.
The Global Cluster Headache Market Demand is expected to witness high growth, exhibiting CAGR of 6.4% over the forecast period, due to increasing prevalence of cluster headaches. The market size for 2023 is US$ 402.12 Mn.
Regional analysis: North America dominates the global cluster headache market, owing to the rising awareness and high healthcare expenditure. Europe market exhibits high growth potential driven by growing patient population. However, Asia Pacific region is expected to showcase fastest growth over the forecast period supported by expanding pharmaceutical industry.
Key players operating in the cluster headache market are Zosano Pharma, Eli Lilly and Company, Lundbeck Seattle BioPharmaceutical, Winston Laboratories, GlaxoSmithKline plc., ElectroCore Medical LLC, Autonomic Technologies, Inc., AstraZeneca plc., Allergan plc., Bayer AG, F. Hoffmann-La Roche Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Sanofi, and AbbVie Inc. These companies dominate with diverse product portfolios and strong global presence.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it